# 508856124 11/06/2024

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 Assignment ID: PATI615350

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
Etienne Sibille	04/03/2017

## **RECEIVING PARTY DATA**

Company Name:	Centre for Addiction and Mental Health	
Street Address:	1001 Queen Street West	
City:	Toronto	
State/Country:	CANADA	
Postal Code:	M6J1H4	

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	18363933

#### **CORRESPONDENCE DATA**

**Fax Number:** 4142770656

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

using a lax number, in provided, in that is unsuccessful, it will be sent via 03 in

**Phone:** (414)271-6560

**Email:** mkeipdocket@michaelbest.com,dahauser@michaelbest.com

Correspondent Name: Dorothy A. Hauser

Address Line 1: Michael Best & Friedrich LLP

Address Line 2: N19 W24133 Riverwood Drive, Ste. 200

Address Line 4: Waukesha, WISCONSIN 53188

ATTORNEY DOCKET NUMBER:	020871-9121-US03	
NAME OF SUBMITTER:	Dorothy Hauser	
SIGNATURE:	Dorothy Hauser	
DATE SIGNED:	11/06/2024	

**Total Attachments: 2** 

source=020871-9121-US03\_As\_Filed\_Assignment\_Etienne\_Sibille#page1.tiff source=020871-9121-US03\_As\_Filed\_Assignment\_Etienne\_Sibille#page2.tiff

PATENT 508856124 REEL: 069162 FRAME: 0327

#### ASSIGNMENT

Pursuant to my obligation to the Centre for Addiction and Mental Health (hereinafter referred to as "Assignee"), an institution having its principal place of business at:

1001 Queen Street West Toronto, Ontario M6J1H4 Canada

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, I:

Etienne Sibille 935087 Airport Road Mono, Ontario L9W 6C6 Canada

confirm my obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, my entire right, title and interest -

- (1) in and to inventions described in a patent application titled "TREATMENTS OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA SELECTIVE AGONISTS" for which we filed International Patent Application No. PCT/US2017/023206, (Atty. File No. 020871-9121-WO00) (hereinafter the "PCT patent application") which application claims the benefit of United States Provisional Patent Application No. 62/310,409, filed March 18, 2016 (hereinafter the "U.S. provisional patent application") (Atty. File No. 020871-9121-US00);
- (2) in and to the PCT patent application, and the U.S. provisional patent application, in and to all other patent applications (including divisional, continuation, continuation-in-part, 35 U.S.C. §111(b) provisional, 35 U.S.C. §111(a), and reissue applications) based upon said inventions, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;
- (3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and
- (4) under the International Convention in respect to the PCT patent application and the U.S. provisional patent application, and agree that any patent applications of any foreign

PATENT REEL: 069162 FRAME: 0328 countries which may be filed shall be filed in the name of my Assignee with a claim to priority based on the PCT patent application and the U.S. provisional patent application.

I hereby authorize the assignee or attorney of record to insert in the appropriate place in this document the application number of my application after execution of this Assignment. I hereby agree that I will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by me.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

April 5, 2017

Etienne Sibille